Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer

Journal of Clinical Oncology

Volumn 18, Issue 11, 2000, Pages 2293-2300

  Fizazi, Karim ^a   Ducreux, Michel ^a   Ruffié, Pierre ^a   Bonnay, Marc ^a   Daniel, Catherine ^a   Soria, Jean Charles ^a   Hill, Catherine ^a   Fandi, Abderrahim ^a   Poterre, Marc ^a   Smith, Mark ^a   Armand, Jean Pierre ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ONDANSETRON; OXALIPLATIN; RALTITREXED;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

EID: 0034121945     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.11.2293     Document Type: Article

References (32)

1. Jackman A, Taylor G, Gibson W, et al: A quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study. Cancer Res 51:5579-5586, 1991
2. Jackman A, Calvert AH: Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 6:871-881, 1995
3. Jackman A, Gibson W, Brown M: The role of the reduced folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D 1654, in Rustrum Y (ed): Proceedings of the International Symposium on Novel Approaches to Selective Treatments of Human Solid Tumors: Laboratory and Clinical Correlation - Advances in Experimental Medicine. New York, NY, Plenum, 1995, pp 265-276
4. Sorensen JM, Jordan E, Grem JL, et al: Phase I trial of ZD 1694 (Tomudex), a direct inhibitor of thymidylate synthase. Ann Oncol 5:132, 1994 (suppl 5, abstr 241)
5. Clarke SJ, Hanwell J, de Boer M, et al: Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor in patients with solid tumors. J Clin Oncol 14:1495-1503, 1996
6. Beale P, Judson I, Hanwell J, et al: Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients. Cancer Chemother Pharmacol 42:71-76, 1998
7. Judson IR: 'Tomudex' (raltitrexed) development: Preclinical, phase I and II studies. Anticancer Drugs 8:S5-S9, 1997 (suppl 2)
8. Zalcberg J, Cunningham D, Van Cutsem E, et al: ZD 1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 14:716-721, 1996
9. Cunningham D, Zalcberg J, Rath U, et al: Final results of a randomized trial comparing "Tomudex" (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 7:961-965, 1996
10. Cocconi G, Cunningham D, Van Cutsem E, et al: Open, randomized multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 16:2943-2952, 1998
11. Pazdur R, Vincent M: Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-Fu + Leu) in patients with advanced colorectal cancer (ACC): Results of a randomized, multicentric, North American trial. Proc Am Soc Clin Oncol 16:228a, 1997 (abstr 801)
12. Cunningham D: Mature results from three large controlled studies with raltitrexed (Tomudex). Br J Cancer 77:15-21, 1998 (suppl 2)
13. Maughan TS, James RD, Kerr D, et al: Preliminary results of a multicenter randomized trial comparing 3 chemotherapy regimens (de Gramont, Lokich and raltitrexed) in metastatic colorectal cancer. Proc Am Soc Clin Oncol 18:262a, 1999 (abstr 1007)
14. Connors TA, Jones M, Ross WC, et al: New platinum complexes with anti-tumor activity. Chem Biol Interact 5:415-424, 1972
15. Burchenal J, Kalaker K, Dew K, et al: Rationale for development of platinum analogs. Cancer Treat Rep 63:1493-1497, 1979
16. Bleiberg H, De Gramont A: Oxaliplatin plus 5-fluorouracil: Clinical experience in patients with advanced colorectal cancer. Semin Oncol 25:32-39, 1998
17. Brienza S, Gastiaburu J, Cvitkovic E, et al: Neurotoxicity (NTX) of long term oxaliplatin (L-OHP, transplatin) therapy. Eur J Cancer 29a:632, 1993 (abstr 632)
18. Brienza S, Vignoud J, Itzhaki M, et al: Oxaliplatin (L-OHP): Global safety in 682 patients (pts). Proc Am Soc Clin Oncol 14: 209a, 1995 (abstr 513)
19. Chollet P, Bensmaine A, Brienza S, et al: Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7:1065-1070, 1996
20. Raymond E, Djelloul S, Buquet-Fagot C, et al: Oxaliplatin (LOHP) and cisplatin (CDDP) in combination with 5FU, specific thymidylate synthase (TS) inhibitors (AG337, ZD1694), and topoisomerase I (topo-I) inhibitors (SN38, CPT-11), in human colonic, ovarian and breast cancers. Proc Am Assoc Cancer Res 37:291, 1996 (abstr 1981)
21. Raymond E, Chaney S, Taamma A, et al: Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 9:1053-1071, 1998
22. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
23. Kamaromy-Hiller G: Flame, flameless and plasma spectroscopy. Analytical Chem 15:338-342, 1999
24. Graham MA, Gamelin E, Misset JL, et al: Clinical pharmacokinetics of oxaliplatin Proc Am Assoc Cancer Res 39:159, 1998 (abstr 1088)
25. de Gramont A, Figer A, Seymour M, et al: A randomized trial of leucovorin (LV) and 5-fluorouracil (5FU) with or without oxaliplatin in advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 17:257a, 1998 (abstr 985)
26. Zori Comba A, Blajman C, Richardet E, et al: Bimonthly oxaliplatin (L-OHP) with (A) or without (B) fluorouracil (FU) and leucovorin (FA): Proven evidence of synergism in a phase II randomised trial. Proc Am Soc Clin Oncol 18:248a, 1999 (abstr 953)
27. Levi F, Zidani R, Misset JL, et al: International Organization for Cancer Chronotherapy: Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 350:681-686, 1997
28. Ford HER, Cunningham D, Ross PJ, et al: Open label dose finding phase I study of irinotecan hydrochloride and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma. Proc Am Soc Clin Oncol 18:176a, 1999 (abstr 678)
29. Nobile MT, Gozza A, Simoni C, et al: Combination phase II study of irinotecan (CPT 11) and raltitrexed (Tomudex) in advanced colorectal cancer. Proc Am Soc Clin Oncol 18:294a, 1999 (abstr 1129)
30. Fizazi K, Viala J, Daniel C, et al: 'Tomudex' (raltitrexed) and oxaliplatin: An active out-patient regimen in malignant mesothelioma. Eur J Cancer 35:S252, 1999 (suppl 4, abstr 1000)
31. Fizazi K, Daniel C, Calliandro R, et al: Tomudex-oxaliplatin: A step ahead in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. Malignant Pleural Mesothelioma Meeting, Lignano Sabbiadoro, Italy, March 18-19, 1999
32. Seitz JF, Douillard JY, Paillot B, et al: 'Tomudex' (raltitrexed) plus oxaliplatin as first-line chemotherapy in metastatic colorectal cancer (MCRC) patients: A promising combination. Proc Am Soc Clin Oncol 18:257a, 1999 (abstr 986)